FDA clears Abbott's ovarian cancer monitoring test
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Abbott's Architect HE4 ovarian cancer blood test. It is designed to monitor patients for recurrence or progression of the disease – 75% of patients experience recurrence, according to the company. However, it is not recommended for screening or in women with mucinous or germ cell tumours, which rarely express HE4. Abbott (Abbott Park, Illinois) hopes its HE4 test, in combination with the current gold-standard ovarian cancer biomarker, CA125, could improve patient monitoring. CA125 is widely used for this purpose, but 20% of ovarian cancers do not express the biomarker, the firm claims. Abbott CE marked the Architect HE4 for sale in Europe earlier this year (www.clinica.co.uk, 15 January 2010).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.